CRISPR-Cas9 has made targeted modification of disease-causing genes possible, and the first therapies based on the technology have already received regulatory approval. But a persistent challenge remains: when CRISPR-Cas9 cuts DNA, cells do not always repair the break as intended. Unintended outcomes—including chromosomal deletions and rearrangements—can occur, carrying unknown safety implications, particularly in stem cells intended for transplantation. A new study published in Nature Biotechnology describes a platform designed to address that problem directly.
The platform, called SMArT (Selection by Means of Artificial Transactivators), was developed at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) by a team led by Luigi Naldini and Samuele Ferrari. It works by verifying that a targeted genetic integration has occurred correctly, then using that confirmation to selectively enrich the cells that achieved the intended outcome while removing those carrying unintended alterations.
"These unintended outcomes, such as large deletions of DNA sequences, have emerged as one of the most important limitations to the broader application of gene editing, especially in stem cells intended for transplantation. With SMArT, we aimed to create an intelligent selection system capable of identifying and enriching only those cells that achieved the desired genetic correction while excluding cells carrying potentially dangerous alterations," said Naldini.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
The researchers developed three increasingly sophisticated SMArT configurations that function as transient synthetic "AND-gate" systems. A selectable marker is only activated in cells that simultaneously carry the intended on-target integration and preserve the integrity of the targeted locus—allowing purification of correctly edited cells to near purity. In preclinical models, SMArT-enriched blood stem cells successfully engrafted in immunodeficient mice and generated long-term human hematopoiesis. Notably, the selector used to isolate correctly edited cells was only transiently expressed and became undetectable after engraftment.
"Our goal was not simply to improve editing efficiency, but to fundamentally rethink how to control the quality of edited cell products," said Ferrari. "SMArT introduces a programmable framework that can simultaneously increase precision, reduce genotoxic burden, and preserve the functional potential of stem cells."
The study focused on editing strategies for severe inherited immune disorders including X-linked severe combined immunodeficiency (SCID-X1) and Hyper-IgM 1 syndrome, but the authors suggest the approach could apply broadly across multiple gene editing platforms and disease areas. One advanced version of the technology, SMArT-3, uses a CRISPR-based regulatory system to transiently detect correct genomic integration and activate endogenous genes that may improve stem cell engraftment.
"Gene editing has often been described as precise genome surgery, but biology is more complex than initially anticipated," said co-first author Daniele Canarutto. "SMArT helps distinguish cells that truly achieved the intended therapeutic outcome from those that underwent alternative repair processes."